| 1 | Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial | 2.9 | 91 | Citations (PDF) |
| 2 | Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease | 19.4 | 580 | Citations (PDF) |
| 3 | Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease | 19.4 | 772 | Citations (PDF) |
| 4 | Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease | 19.4 | 347 | Citations (PDF) |
| 5 | A Risk Assessment Tool Incorporating New Biomarkers for Cardiovascular Events in Acute Coronary Syndromes: The Organization to Assess Strategies in Ischemic Syndromes (OASIS) Risk Score | 1.5 | 10 | Citations (PDF) |
| 6 | Community health worker-based intervention for adherence to drugs and lifestyle change after acute coronary syndrome: a multicentre, open, randomised controlled trial | 12.5 | 111 | Citations (PDF) |
| 7 | Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation | 1.8 | 19 | Citations (PDF) |
| 8 | Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics | 1.5 | 28 | Citations (PDF) |
| 9 | Extracranial Systemic Embolic Events in Patients With Nonvalvular Atrial Fibrillation | 13.1 | 114 | Citations (PDF) |
| 10 | Methylprednisolone in patients undergoing cardiopulmonary bypass (SIRS): a randomised, double-blind, placebo-controlled trial | 45.2 | 347 | Citations (PDF) |
| 11 | Identifying Novel Biomarkers for Cardiovascular Events or Death in People With Dysglycemia | 13.1 | 69 | Citations (PDF) |
| 12 | Modifiable lifestyle and social factors affect chronic kidney disease in high-risk individuals with type 2 diabetes mellitus | 4.6 | 114 | Citations (PDF) |
| 13 | Systolic and Diastolic Blood Pressure Changes in Relation With Myocardial Infarction and Stroke in Patients With Coronary Artery Disease | 4.7 | 78 | Citations (PDF) |
| 14 | Prospective long-term evaluation of Optim-insulated (Riata ST Optim and Durata) implantable cardioverter-defibrillator leads | 1.8 | 30 | Citations (PDF) |
| 15 | Aliskiren alone or with other antihypertensives in the elderly with borderline and stage 1 hypertension: the APOLLO trial | 2.6 | 27 | Citations (PDF) |
| 16 | Prognostic Usefulness of Left Ventricular Hypertrophy by Electrocardiography in Patients With Atrial Fibrillation (from the Randomized Evaluation of Long-Term Anticoagulant Therapy Study) | 1.5 | 16 | Citations (PDF) |
| 17 | Clonidine in Patients Undergoing Noncardiac Surgery | 19.4 | 349 | Citations (PDF) |
| 18 | The statistical significance of randomized controlled trial results is frequently fragile: a case for a Fragility Index | 2.4 | 734 | Citations (PDF) |
| 19 | The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study | 13.1 | 200 | Citations (PDF) |
| 20 | Causes of Death and Influencing Factors in Patients With Atrial Fibrillation | 13.1 | 302 | Citations (PDF) |
| 21 | Cardiovascular Risk in Patients with Early Renal Insufficiency | 1.9 | 10 | Citations (PDF) |
| 22 | Prognostic utility and characterization of cell-free DNA in patients with severe sepsis | 4.1 | 289 | Citations (PDF) |
| 23 | Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia | 19.4 | 1,545 | Citations (PDF) |
| 24 | Designing and Analyzing Clinical Trials with Composite Outcomes: Consideration of Possible Treatment Differences between the Individual Outcomes | 1.5 | 47 | Citations (PDF) |
| 25 | Characteristics and Short-Term Prognosis of Perioperative Myocardial Infarction in Patients Undergoing Noncardiac Surgery | 7.3 | 623 | Citations (PDF) |
| 26 | Net Clinical Benefit of Adding Clopidogrel to Aspirin Therapy in Patients With Atrial Fibrillation for Whom Vitamin K Antagonists Are Unsuitable | 7.3 | 129 | Citations (PDF) |
| 27 | Irbesartan in Patients with Atrial Fibrillation | 19.4 | 239 | Citations (PDF) |
| 28 | Testing for heterogeneity among the components of a binary composite outcome in a clinical trial | 1.7 | 24 | Citations (PDF) |
| 29 | Low-Dose vs Standard-Dose Unfractionated Heparin for Percutaneous Coronary Intervention in Acute Coronary Syndromes Treated With Fondaparinux: The FUTURA/OASIS-8 Randomized Trial | 15.8 | 180 | Citations (PDF) |
| 30 | Dabigatran and Warfarin in Vitamin K Antagonist–Naive and –Experienced Cohorts With Atrial Fibrillation | 13.1 | 159 | Citations (PDF) |
| 31 | Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W | 2.6 | 35 | Citations (PDF) |
| 32 | Cognitive Function and Anticoagulation Control in Patients With Atrial Fibrillation | 2.8 | 102 | Citations (PDF) |
| 33 | Fondaparinux with UnfracTionated heparin dUring Revascularization in Acute coronary syndromes (FUTURA/OASIS 8): A randomized trial of intravenous unfractionated heparin during percutaneous coronary intervention in patients with non–ST-segment elevation acute coronary syndromes initially treated with fondaparinux | 1.8 | 21 | Citations (PDF) |
| 34 | Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial | 45.2 | 948 | Citations (PDF) |
| 35 | Referrals in Acute Coronary Events for CARdiac Catheterization: The RACE CAR trial | 1.5 | 9 | Citations (PDF) |
| 36 | Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation | 19.4 | 1,333 | Citations (PDF) |
| 37 | The Family Atherosclerosis Monitoring In earLY life (FAMILY) study | 1.8 | 57 | Citations (PDF) |
| 38 | Dabigatran versus Warfarin in Patients with Atrial Fibrillation | 19.4 | 10,698 | Citations (PDF) |
| 39 | Effect of Telmisartan on Renal Outcomes | 7.3 | 172 | Citations (PDF) |
| 40 | Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events | 19.4 | 3,384 | Citations (PDF) |
| 41 | Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial | 45.2 | 2,185 | Citations (PDF) |
| 42 | Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial | 45.2 | 1,500 | Citations (PDF) |
| 43 | Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial | 45.2 | 948 | Citations (PDF) |
| 44 | Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study | 2.6 | 121 | Citations (PDF) |
| 45 | Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range | 13.1 | 828 | Citations (PDF) |
| 46 | Risks and Benefits of Oral Anticoagulation Compared With Clopidogrel Plus Aspirin in Patients With Atrial Fibrillation According to Stroke Risk | 4.4 | 180 | Citations (PDF) |
| 47 | The need to test the theories behind the Polypill: rationale behind the Indian Polycap Study | 0.5 | 15 | Citations (PDF) |
| 48 | Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation | 13.1 | 83 | Citations (PDF) |
| 49 | Effect of long-term ACE-inhibitor therapy in elderly vascular disease patients | 2.6 | 31 | Citations (PDF) |
| 50 | Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies | 2.6 | 922 | Citations (PDF) |
| 51 | Incidence of Stroke in Paroxysmal Versus Sustained Atrial Fibrillation in Patients Taking Oral Anticoagulation or Combined Antiplatelet Therapy | 0.7 | 448 | Citations (PDF) |
| 52 | Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial | 45.2 | 1,895 | Citations (PDF) |
| 53 | Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials | 45.2 | 478 | Citations (PDF) |
| 54 | Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes | 19.4 | 1,164 | Citations (PDF) |
| 55 | Homocysteine Lowering with Folic Acid and B Vitamins in Vascular Disease | 19.4 | 1,651 | Citations (PDF) |
| 56 | Impact of Ramipril on the Circadian Periodicity of Acute Myocardial Infarction | 1.5 | 10 | Citations (PDF) |
| 57 | Reevaluation by High-Performance Liquid Chromatography: Clinical Significance of Microalbuminuria in Individuals at High Risk of Cardiovascular Disease in the Heart Outcomes Prevention Evaluation (HOPE) Study | 1.0 | 28 | Citations (PDF) |
| 58 | Effect of angiotensin‐converting enzyme inhibition on functional class in patients with left ventricular systolic dysfunction—a meta‐analysis | 4.7 | 26 | Citations (PDF) |
| 59 | The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis | 4.8 | 241 | Citations (PDF) |
| 60 | ACE Inhibition in Stable Coronary Artery Disease | 19.4 | 45 | Citations (PDF) |
| 61 | Long-Term Effects of Ramipril on Cardiovascular Events and on Diabetes | 13.1 | 175 | Citations (PDF) |
| 62 | Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease | 1.8 | 309 | Citations (PDF) |
| 63 | Effect of Ramipril in Reducing Sudden Deaths and Nonfatal Cardiac Arrests in High-Risk Individuals Without Heart Failure or Left Ventricular Dysfunction | 13.1 | 63 | Citations (PDF) |
| 64 | Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: Results of the HOPE Study | 4.6 | 110 | Citations (PDF) |
| 65 | Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial | 4.8 | 160 | Citations (PDF) |
| 66 | Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials | 1.8 | 393 | Citations (PDF) |
| 67 | Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patients | 2.2 | 25 | Citations (PDF) |
| 68 | Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study | 13.1 | 212 | Citations (PDF) |
| 69 | Cost Implications of the Use of Ramipril in High-Risk Patients Based on the Heart Outcomes Prevention Evaluation (HOPE) Study | 13.1 | 60 | Citations (PDF) |
| 70 | Relationship of Activated Partial Thromboplastin Time to Coronary Events and Bleeding in Patients With Acute Coronary Syndromes Who Receive Heparin | 13.1 | 103 | Citations (PDF) |
| 71 | Efficacy of hirudin in reducing cardiovascular events in patients with acute coronary syndrome undergoing early percutaneous coronary intervention | 2.6 | 26 | Citations (PDF) |
| 72 | Use of ramipril in preventing stroke: double blind randomised trial | 0.1 | 368 | Citations (PDF) |
| 73 | Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review | 45.2 | 230 | Citations (PDF) |
| 74 | Blood-pressure reduction and cardiovascular risk in HOPE study | 45.2 | 228 | Citations (PDF) |
| 75 | Renal Insufficiency as a Predictor of Cardiovascular Outcomes and the Impact of Ramipril: The HOPE Randomized Trial | 7.3 | 1,274 | Citations (PDF) |
| 76 | Safety Outcomes in Meta-analyses of Phase 2 vs Phase 3 Randomized Trials | 15.8 | 30 | Citations (PDF) |
| 77 | Vitamin E Supplementation and Cardiovascular Events in High-Risk Patients | 19.4 | 1,918 | Citations (PDF) |
| 78 | Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients | 45.2 | 1,471 | Citations (PDF) |
| 79 | Functional capacity in patients with congestive heart failure | 0.9 | 30 | Citations (PDF) |
| 80 | Relationship of glucose and insulin levels to the risk of myocardial infarction: a case-control study | 0.7 | 94 | Citations (PDF) |
| 81 | Overcoming the limitations of current meta-analysis of randomised controlled trials | 45.2 | 427 | Citations (PDF) |
| 82 | Elevated lipoprotein(a) levels in South Asians in North America | 9.0 | 92 | Citations (PDF) |
| 83 | Primary Angioplasty Compared With Thrombolytic Therapy for Acute Myocardial Infarction | 15.8 | 18 | Citations (PDF) |
| 84 | Study Design and Baseline Characteristics of the Study to Evaluate Carotid Ultrasound Changes in Patients Treated with Ramipril and Vitamin E: SECURE**This study was supported by Research Grant Ul-12363 from the Medicine Research Council of Canada, Ottawa; and by Hoechst Marion Roussel, Laval, Canada, Inc. | 1.5 | 35 | Citations (PDF) |
| 85 | Rationale and Design of a Large Study to Evaluate the Renal and Cardiovascular Effects of an ACE Inhibitor and Vitamin E in High-Risk Patients With Diabetes: The MICRO-HOPE Study | 6.5 | 69 | Citations (PDF) |
| 86 | 63A Utilizing sequential monitoring boundaries for cumulative meta-analysis | 2.8 | 1 | Citations (PDF) |
| 87 | P300 latency indexes nitrogen narcosis | 2.5 | 11 | Citations (PDF) |
| 88 | Weighted Multiple Testing Correction for Correlated Binary Endpoints | 0.8 | 0 | Citations (PDF) |
